 - In ovarian cancer, the standard treatment for patients relapsing during bevacizumab maintenance 15 to 20 of patients is still a mono-chemotherapy. Weekly paclitaxel is one oh the most commonly used chemotherapy in this situation of early relapse. However, the promising results of pazopanib in first line led to develop protocols in second-line in combination with chemotherapy. 